Suppr超能文献

慢性胰腺炎患者接受全胰切除术后的移植选择。

Transplant options for patients undergoing total pancreatectomy for chronic pancreatitis.

作者信息

Gruessner Rainer W G, Sutherland David E R, Dunn David L, Najarian John S, Jie Tun, Hering Bernhard J, Gruessner Angelika C

机构信息

Department of Surgery, University of Minnesota, MMC 90, 420 Delaware Street SE, Minneapolis, MN 55455, USA.

出版信息

J Am Coll Surg. 2004 Apr;198(4):559-67; discussion 568-9. doi: 10.1016/j.jamcollsurg.2003.11.024.

Abstract

BACKGROUND

Total pancreatectomy to treat chronic pancreatitis is associated with severe diabetic control problems in 15% to 75% of patients, causing up to 50% of deaths late postoperatively. We report our experience with islet autotransplants at the time of, or with pancreas allotransplants after, total pancreatectomy.

STUDY DESIGN

Between February 1, 1977, and June 30, 2003, we performed 112 islet autotransplants at the time of total pancreatectomy; we also performed 20 pancreas allotransplants in 13 patients who had already undergone total pancreatectomy months to years earlier.

RESULTS

Islet autotransplants at the time of total pancreatectomy in patients who had not had previous operations on the body and tail of the pancreas were associated with a high islet yield (>2,500 islet equivalents/kg body weight), and >70% of the recipients achieved complete insulin independence. In contrast, a previous distal pancreatectomy or a Puestow drainage procedure was associated with a low islet yield in 75% of them and with complete insulin independence in <20%. A pancreas allotransplant after total pancreatectomy was not associated with any transplant-related mortality at 1 and 3 years posttransplant. The pancreas graft survival rate at 1 year posttransplant was 77% with tacrolimus-based immunosuppression (versus 67% with cyclosporine). Enteric (over bladder) drainage was preferred to manage exocrine graft secretions, to cure pancreatectomy-induced endocrine and exocrine insufficiency.

CONCLUSIONS

Our series shows that pancreas allotransplants can be performed without transplant-related mortality and, when tacrolimus-based immunosuppression is used, with 1-year pancreas graft survival rates >75%. In contrast to a simultaneous islet autotransplant, a pancreas allotransplant has the disadvantage of requiring lifelong immunosuppression, but the advantage of not only curing endocrine but also exocrine insufficiency. Both transplant options, if successful, improve the recipient's quality of life.

摘要

背景

全胰切除术治疗慢性胰腺炎时,15%至75%的患者会出现严重的糖尿病控制问题,导致术后晚期高达50%的患者死亡。我们报告了在全胰切除术时或之后进行胰岛自体移植以及胰腺同种异体移植的经验。

研究设计

1977年2月1日至2003年6月30日期间,我们在全胰切除术时进行了112例胰岛自体移植;我们还对13例数月至数年之前已接受全胰切除术的患者进行了20例胰腺同种异体移植。

结果

未对胰体和胰尾进行过先前手术的患者在全胰切除术时进行胰岛自体移植,胰岛产量较高(>2500胰岛当量/千克体重),超过70%的受者实现了完全胰岛素自主。相比之下,先前的胰体尾切除术或普埃斯托引流术在75%的患者中导致胰岛产量较低,且<20%的患者实现完全胰岛素自主。全胰切除术后的胰腺同种异体移植在移植后1年和3年时与任何移植相关死亡率均无关。基于他克莫司的免疫抑制方案使移植后1年的胰腺移植物存活率为77%(而基于环孢素的方案为67%)。对于外分泌性移植物分泌物的处理,肠内(优于膀胱)引流更受青睐,以治愈全胰切除术后引起的内分泌和外分泌功能不全。

结论

我们的系列研究表明,胰腺同种异体移植可以在无移植相关死亡率的情况下进行,并且当使用基于他克莫司的免疫抑制方案时,移植后1年的胰腺移植物存活率>75%。与同期胰岛自体移植相比,胰腺同种异体移植的缺点是需要终身免疫抑制,但优点是不仅能治愈内分泌功能不全,还能治愈外分泌功能不全。如果成功,这两种移植选择都能改善受者的生活质量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验